Dr. Nandagopal Velayuthaswamy

Dr. Nandagopal Velayuthaswamy
Pulmonologist, Coimbatore

MD (Tuberculosis and Respiratory Diseases)

  • 2 Hospitals
  • 13 Years Experience
  • Dr. Nandagopal Velayuthaswamy is a Consultant at G. Kuppuswamy Naidu Memorial Hospital, Karthik Poly Clinic, Coimbatore

Specialities

  • Pulmonology

  • Respiratory Medicine

  • Sleep Medicine

Conditions

  • Respiratory Disorders

  • Tuberculosis

Expertise

Education

  • MBBS from Dr. MGR Medical University, Tamilnadu in 1996
  • MD from Dr. MGR Medical University, Tamilnadu in 2003

Practice Information

G. Kuppuswamy Naidu Memorial Hospital, Coimbatore

G. Kuppuswamy Naidu Memorial Hospital, Coimbatore

P.B. No. 6327, Nethaji Road, Pappanaickenpalayam, Coimbatore, Tamil Nadu - 641037

MON & WED & FRI

08:00 AM - 01:00 PM

Karthik Poly Clinic, Coimbatore

Karthik Poly Clinic, Coimbatore

#101, Karunandhi Nagar, Trichy Road, Coimbatore, Tamil Nadu - 641045

MON - FRI

03:00 PM - 08:00 PM

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Nandagopal Velayuthaswamy and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Clinical Trial: Study on evaluation of the efficacy and safety of the addition of tiotropium bromide to inhaled corticosteroid and long acting beta agonist combination in moderate to severe COPD patients. 2007.
  • Clinical Trial: Study on a randomised, double-blind, double-dummy, placebo-controlled, five period, crossover, single dose study to evaluate equivalence in bronchodilatory effect of each of the two doses (42/240 µg and 168/960 µg ) of a CFC combination of Ipratropium Bromide and Salbutamol Sulphate PMDI to the corresponding two doses of an HFA combination of Ipratropium Bromide and Salbutamol Sulphate PMDI in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD).
  • Clinical Trial: Study on a randomised, double-blind, double-dummy four period crossover study to determine the therapeutic equivalence of a test HFA formulation of Salbutamol Sulphate with the reference HFA formulation of Salbutamol Sulphate in subjects with stable mild to moderate asthma.
  • Clinical Trial: Study on a 26-week treatment multi-centre, randomised, double-blind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of 110/50 µg Q.D. in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
  • Clinical Trial: Study on a Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of Tiotropium Inhalation Solution (2.5 And 5 µg once daily) compared with placebo and Salmeterold HFA MDI (50 µg Twice Daily) over 24 weeks in patients with moderate persistent asthma.
  • Clinical Trial: Study on a Phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of Tiotropium Inhalation solution (2.5 µg and 5 µg once daily) compared to placebo over 12 weeks in mild persistent asthma.
  • Clinical Trial: Study on a 12-week treatment, randomised, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 ug o.d.) compared to Tiotropium (18 ug o.d) in patient with chronic obstructive pulmonary disease (COPD).
  • Clinical Trial: Study on a randomised, active controlled, double-blind, double-dummy, parallel group, design, multi-centre, trial to compare the efficacy and safety Of 2.5 µg and 5 µg Tiotropium inhalation solution with Tiotropium inhalation capsules 18 µg.
  • Clinical Trial: Study on an international, multi-centre, open, parallel group, prospective, randomised, controlled trial to determine the effectiveness of treatment with continuous positive airways pressure (CPAP) in addition to standard care in reducing cardiovascular (CV) morbidity and mortality in patients with co-existing CV disease and moderate-severe obstructive sleep apnea (OSA). [Discontinued Study]
  • Clinical Trial: Study on a 52-week treatment, multi-centre, randomised, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD. [Current Study]
  • Phase III. 3B ASTHMA [2001-2002]. 1 Trial. Indian. ICH-GCP compliant. 30 Patients/6 Months. Completed.
  • Phase III. 3B COPD [2001-2003]. 1 Trial. Global. ICH-GCP compliant. 60 Patients/10 Months. Completed.
  • Phase III. 3B COPD [2002-2003]. 1 Trial. Indian. 20 Patients/4 Months. Completed.
  • Phase III. 3B COPD [2007]. 1 Trial. Indian. ICH-GCP compliant.
  • Phase III. 3B COPD [2008]. 1 Trial. Indian. ICH-GCP compliant. 20 Patients/2 Months. Completed.
  • Phase III. 3-ASTHMA. 1 Trial. Indian. ICH-GCP compliant. 15 Patients. Completed.
  • Phase III. 3B-ASTHMA. [2010]. 1 Trial. Indian. ICH-GCP compliant. 19 Patients/6 Months. Completed.
  • Phase III. 3B COPD [2010]. 1 Trial. Global. ICH-GCP compliant. 10 Patients. Ongoing.
  • Phase III. 3B COPD [2010]. 1 Trial. Global. ICH-GCP compliant. 33 Patients. Ongoing.
  • Phase III. 3B COPD [2011]. 1 Trial. Global. ICH-GCP compliant. 6 Patients. Completed.
  • Phase III. 3B COPD [2012-2013]. 1 Trial. Global. ICH-GCP compliant. 11 Patients. Completed.
  • Triple Gold Medalist in MD Exams
  • Member, European Respiratory Society (ERS).
  • Member, Indian Sleep Disorder Association (ISDA).
  • Member, Indian Chest Society.
  • Member, Coimbatore Chest Club.
  • Member, Infectious Disease Society Association (IDSA).
  • Member, American College of Chest Physicians (ACCP).
  • Member, Indian Medical Association (IMA).